Quebec officials announced plans to tighten the sale of over‑the‑counter Benadryl following the 2023 death of an 18‑year‑old who overdosed on the medication. The proposal comes after a 2025 recommendation from the province's coroner, who called for tighter controls on the antihistamine.
The coroner’s report linked the fatal overdose to the ease of access to Benadryl without a prescription. In response, the Quebec government said it is reviewing regulations that would limit how the product is sold to the public. While specific measures have not been detailed, the move signals a shift toward greater oversight of an antihistamine that can be purchased at pharmacies and other retail outlets.
The 2023 incident, involving a teenager, has drawn attention to the potential for misuse of common allergy medicines. Health officials have noted that Benadryl, while safe when used as directed, can be dangerous in excessive quantities. The provincial authorities intend to assess the current framework governing over‑the‑counter medications and consider options that could include age restrictions, quantity limits, or additional labeling requirements.
Quebec's health ministry indicated that the initiative aligns with broader public‑health efforts to prevent accidental poisonings and intentional misuse of readily available drugs. The proposed changes are expected to be debated within the provincial cabinet and may be presented to the legislative assembly for approval later this year.
If adopted, the regulations would mark the first major provincial action in Canada targeting the sale of an antihistamine after a fatal overdose. The government hopes the steps will reduce the risk of similar incidents and protect vulnerable consumers, particularly young people, from the dangers of unsupervised consumption of high‑dose antihistamines.